Advertisement

Epidemiology and Pathogenesis of Hepatocellular Carcinoma

  • Manal M. Hassan
  • Ahmed O. Kaseb
Chapter

Abstract

Liver cancer is the sixth most common cancer worldwide and the third most common cause of cancer mortality, with more than 500,000 deaths annually [1, 2]. Hepatocellular carcinoma (HCC), which comprises most primary liver cancer cases, is rarely detected early and is usually fatal within a few months of diagnosis [3]. A recently published study indicated that the incidence rates of HCC tripled in the United States from 1975 through 2005 [4].

Keywords

Hepatocellular carcinoma HCC HCC incidence HCC risk factors Diabetes mellitus HBV HCV 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRefGoogle Scholar
  3. 3.
    Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23:2892–2899PubMedCrossRefGoogle Scholar
  4. 4.
    Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491PubMedCrossRefGoogle Scholar
  5. 5.
    McGlynn KA, London WT (2005) Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19:3–23PubMedCrossRefGoogle Scholar
  6. 6.
    El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRefGoogle Scholar
  7. 7.
    International Agency for Research on Cancer (IARC) (1994) Monographs on the evaluation of carcinogenic risks to humans. Hepatitis Viruses 59:182–221Google Scholar
  8. 8.
    Kew MC, Welschinger R, Viana R (2008) Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. J Gastroenterol Hepatol 23:1426–1430PubMedCrossRefGoogle Scholar
  9. 9.
    Zanetti AR, Van DP, Shouval D (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26:6266–6273PubMedCrossRefGoogle Scholar
  10. 10.
    Brechot C (1987) Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications. J Hepatol 4:269–279PubMedCrossRefGoogle Scholar
  11. 11.
    Brechot C, Pourcel C, Louise A, Rain B, Tiollais P (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286:533–535PubMedCrossRefGoogle Scholar
  12. 12.
    Rossner MT (1992) Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 36:101–117PubMedCrossRefGoogle Scholar
  13. 13.
    Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L et al (1992) Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 116:97–102PubMedGoogle Scholar
  14. 14.
    Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y et al (1988) Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 69(Pt 10):2575–2583PubMedCrossRefGoogle Scholar
  15. 15.
    Kidd-Ljunggren K, Miyakawa Y, Kidd AH (2002) Genetic variability in hepatitis B viruses. J Gen Virol 83:1267–1280PubMedGoogle Scholar
  16. 16.
    Kramvis A, Kew M, Francois G (2005) Hepatitis B virus genotypes. Vaccine 23:2409–2423PubMedCrossRefGoogle Scholar
  17. 17.
    Alexopoulou A, Dourakis SP (2005) Genetic heterogeneity of hepatitis viruses and its clinical significance. Curr Drug Targets Inflamm Allergy 4:47–55PubMedCrossRefGoogle Scholar
  18. 18.
    Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C et al (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 88:2451–2455PubMedCrossRefGoogle Scholar
  19. 19.
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshizawa H (2002) Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62(Suppl 1):8–17PubMedCrossRefGoogle Scholar
  21. 21.
    Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:347–354PubMedCrossRefGoogle Scholar
  22. 22.
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von OJ, Lloyd AR et al (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34:809–816PubMedCrossRefGoogle Scholar
  23. 23.
    Parola M, Robino G (2001) Oxidative stress-related molecules and liver fibrosis. J Hepatol 35:297–306PubMedCrossRefGoogle Scholar
  24. 24.
    Cerutti PA (1994) Oxy-radicals and cancer. Lancet 344:862–863PubMedCrossRefGoogle Scholar
  25. 25.
    Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313(Pt 1):17–29PubMedGoogle Scholar
  26. 26.
    Marra F (1999) Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31:1120–1130PubMedCrossRefGoogle Scholar
  27. 27.
    Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21:49–98PubMedCrossRefGoogle Scholar
  28. 28.
    Simmonds P (1995) Variability of hepatitis C virus. Hepatology 21:570–583PubMedCrossRefGoogle Scholar
  29. 29.
    Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S et al (1994) Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19:13–18PubMedCrossRefGoogle Scholar
  30. 30.
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C (1995) Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 122:161–168PubMedGoogle Scholar
  31. 31.
    Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S et al (1995) Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21:285–290PubMedGoogle Scholar
  32. 32.
    De Mitri MS, Poussin K, Baccarini P, Pontisso P, D’Errico A, Simon N et al (1995) HCV-associated liver cancer without cirrhosis. Lancet 345:413–415PubMedCrossRefGoogle Scholar
  33. 33.
    International Agency for Research on Cancer (IARC) (1988) Monographs on the evaluation of carcinogenic risks to humans. Alcohol Drinking 44(44):207–215Google Scholar
  34. 34.
    Batey RG, Burns T, Benson RJ, Byth K (1992) Alcohol consumption and the risk of cirrhosis. Med J Aust 156:413–416PubMedGoogle Scholar
  35. 35.
    Brechot C, Nalpas B, Feitelson MA (1996) Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med 16:273–287PubMedGoogle Scholar
  36. 36.
    Morgan TR, Mandayam S, Jamal MM (2004) Alcohol and hepatocellular carcinoma. Gastroenterology 127:S87–S96Google Scholar
  37. 37.
    Stewart S, Jones D, Day CP (2001) Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 7:408–413PubMedCrossRefGoogle Scholar
  38. 38.
    Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT et al (2008) Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 123:1883–1891PubMedCrossRefGoogle Scholar
  39. 39.
    Mancinelli R, Binetti R, Ceccanti M (2007) Woman, alcohol and environment: emerging risks for health. Neurosci Biobehav Rev 31:246–253PubMedCrossRefGoogle Scholar
  40. 40.
    Ely M, Hardy R, Longford NT, Wadsworth ME (1999) Gender differences in the relationship between alcohol consumption and drink problems are largely accounted for by body water. Alcohol Alcohol 34:894–902PubMedGoogle Scholar
  41. 41.
    Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW et al (2001) Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 25:502–507PubMedCrossRefGoogle Scholar
  42. 42.
    Frezza M, di PC, Pozzato G, Terpin M, Baraona E, Lieber CS (1990) High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95–99PubMedCrossRefGoogle Scholar
  43. 43.
    Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M et al (1994) Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 20:1115–1120PubMedCrossRefGoogle Scholar
  44. 44.
    Paronetto F (1993) Immunologic reactions in alcoholic liver disease. Semin Liver Dis 13:183–195PubMedCrossRefGoogle Scholar
  45. 45.
    International Agency for Research on Cancer (2004) (IARC) Monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking 83:161–176Google Scholar
  46. 46.
    Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P et al (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122:155–164PubMedCrossRefGoogle Scholar
  47. 47.
    International Agency for Research on Cancer (IARC) (2004) Monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking 83:161–176.Google Scholar
  48. 48.
    Franceschi S, Montella M, Polesel J, La VC, Crispo A, Dal ML et al (2006) Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 15:683–689PubMedCrossRefGoogle Scholar
  49. 49.
    Mori M, Hara M, Wada I, Hara T, Yamamoto K, Honda M et al (2000) Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 151:131–139PubMedGoogle Scholar
  50. 50.
    Wang LY, Chen CJ, Zhang YJ, Tsai WY, Lee PH, Feitelson MA et al (1998) 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol 147:315–323PubMedGoogle Scholar
  51. 51.
    Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8:346–355PubMedCrossRefGoogle Scholar
  52. 52.
    Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603PubMedCrossRefGoogle Scholar
  53. 53.
    Frei B, Forte TM, Ames BN, Cross CE (1991) Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 277(Pt 1):133–138PubMedGoogle Scholar
  54. 54.
    Miro O, Alonso JR, Jarreta D, Casademont J, Urbano-Marquez A, Cardellach F (1999) Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes. Carcinogenesis 20:1331–1336PubMedCrossRefGoogle Scholar
  55. 55.
    Ueno Y (1985) The toxicology of mycotoxins. Crit Rev Toxicol 14:99–132PubMedCrossRefGoogle Scholar
  56. 56.
    Guengerich FP, Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391–407PubMedCrossRefGoogle Scholar
  57. 57.
    Guengerich FP, Shimada T, Iwasaki M, Butler MA, Kadlubar FF (1990) Activation of carcinogens by human liver cytochromes P-450. Basic Life Sci 53:381–396PubMedGoogle Scholar
  58. 58.
    Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA (1982) A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 11:112–119PubMedCrossRefGoogle Scholar
  59. 59.
    Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE (1989) Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 49:2506–2509PubMedGoogle Scholar
  60. 60.
    Maheshwari S, Sarraj A, Kramer J, El-Serag HB (2007) Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 47:506–513PubMedCrossRefGoogle Scholar
  61. 61.
    De B, V, Welsh JA, Yu MC, Bennett WP (1996) p53 mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 17:145–149CrossRefGoogle Scholar
  62. 62.
    Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy–long-term follow-up of a Swedish cohort. Int J Cancer 67:327–332PubMedCrossRefGoogle Scholar
  63. 63.
    Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La VC (2003) Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105:408–412PubMedCrossRefGoogle Scholar
  64. 64.
    Boffetta P, Matisane L, Mundt KA, Dell LD (2003) Meta-analysis of studies of occupational exposure to vinyl chloride in relation to cancer mortality. Scand J Work Environ Health 29:220–229PubMedGoogle Scholar
  65. 65.
    Dragani TA, Zocchetti C (2008) Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. Cancer Causes Control 19:1193–1200PubMedCrossRefGoogle Scholar
  66. 66.
    El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRefGoogle Scholar
  67. 67.
    Bell DS, Allbright E (2007) The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract 13:300–312PubMedGoogle Scholar
  68. 68.
    Tolman KG, Fonseca V, Tan MH, Dalpiaz A (2004) Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 141:946–956PubMedGoogle Scholar
  69. 69.
    Harrison SA (2006) Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 40:68–76PubMedCrossRefGoogle Scholar
  70. 70.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539PubMedCrossRefGoogle Scholar
  71. 71.
    Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856–1862PubMedCrossRefGoogle Scholar
  72. 72.
    Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101:1009–1017PubMedCrossRefGoogle Scholar
  73. 73.
    Yu MC, Tong MJ, Govindarajan S, Henderson BE (1991) Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83:1820–1826PubMedCrossRefGoogle Scholar
  74. 74.
    El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468PubMedCrossRefGoogle Scholar
  75. 75.
    Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL et al (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–121PubMedCrossRefGoogle Scholar
  76. 76.
    Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213PubMedCrossRefGoogle Scholar
  77. 77.
    Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K et al (2007) Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 102:1939–1946PubMedCrossRefGoogle Scholar
  78. 78.
    Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K et al (1998) Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 27:1567–1571PubMedCrossRefGoogle Scholar
  79. 79.
    Dellon ES, Shaheen NJ (2005) Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology 129:1132–1134PubMedCrossRefGoogle Scholar
  80. 80.
    Bugianesi E (2005) Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther 22(Suppl 2):40–43PubMedCrossRefGoogle Scholar
  81. 81.
    Moore MA, Park CB, Tsuda H (1998) Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 7:89–107PubMedCrossRefGoogle Scholar
  82. 82.
    Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A (2004) An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68:1003–1015PubMedCrossRefGoogle Scholar
  83. 83.
    Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR (1997) Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26:598–604PubMedCrossRefGoogle Scholar
  84. 84.
    Tanaka S, Wands JR (1996) Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 56:3391–3394PubMedGoogle Scholar
  85. 85.
    Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S et al (2002) The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 23:1781–1789PubMedCrossRefGoogle Scholar
  86. 86.
    Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290:G852–G858PubMedCrossRefGoogle Scholar
  87. 87.
    Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152PubMedGoogle Scholar
  88. 88.
    Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97:1005–1008PubMedGoogle Scholar
  89. 89.
    Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127:S97–S103Google Scholar
  90. 90.
    Xu L, Han C, Lim K, Wu T (2006) Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 66:11859–11868PubMedCrossRefGoogle Scholar
  91. 91.
    Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470–477PubMedCrossRefGoogle Scholar
  92. 92.
    Pucci E, Chiovato L, Pinchera A (2000) Thyroid and lipid metabolism. Int J Obes Relat Metab Disord 24(Suppl 2):S109–S112Google Scholar
  93. 93.
    Krotkiewski M (2000) Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S116–S119Google Scholar
  94. 94.
    Dimitriadis G, Parry-Billings M, Bevan S, Leighton B, Krause U, Piva T et al (1997) The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. Eur J Clin Invest 27:475–483PubMedCrossRefGoogle Scholar
  95. 95.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183–1192PubMedCrossRefGoogle Scholar
  96. 96.
    Liangpunsakul S, Chalasani N (2003) Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37:340–343PubMedCrossRefGoogle Scholar
  97. 97.
    Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN et al (2007) Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol 5:118–123PubMedCrossRefGoogle Scholar
  98. 98.
    Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK et al (2010) Duration of Diabetes and type of diabetes treatment, increase the risk of hepatocellular carcinoma. Cancer 116:1938–1946Google Scholar
  99. 99.
    Haffner SM (2000) Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 24(Suppl 2):S56–S58Google Scholar
  100. 100.
    Hautanen A (2000) Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S64–S70Google Scholar
  101. 101.
    Hampl R, Kancheva R, Hill M, Bicikova M, Vondra K (2003) Interpretation of sex hormone-binding globulin levels in thyroid disorders. Thyroid 13:755–760PubMedCrossRefGoogle Scholar
  102. 102.
    Tanaka K, Sakai H, Hashizume M, Hirohata T (2000) Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60:5106–5110PubMedGoogle Scholar
  103. 103.
    Conte D, Fraquelli M, Fornari F, Lodi L, Bodini P, Buscarini L (1999) Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey. Arch Intern Med 159:49–52PubMedCrossRefGoogle Scholar
  104. 104.
    Conte D, Barisani D, Mandelli C, Bodini P, Borzio M, Pistoso S et al (1991) Cholelithiasis in cirrhosis: analysis of 500 cases. Am J Gastroenterol 86:1629–1632PubMedGoogle Scholar
  105. 105.
    Fornari F, Civardi G, Buscarini E, Cavanna L, Imberti D, Rossi S et al (1990) Cirrhosis of the liver. A risk factor for development of cholelithiasis in males. Dig Dis Sci 35:1403–1408PubMedCrossRefGoogle Scholar
  106. 106.
    Zhu JF, Shan LC, Chen WH (1994) [Changes in lipids, bilirubin and metal elements in the gallbladder bile in patients with cirrhosis of the liver]. Zhonghua Nei Ke Za Zhi 33:767–769PubMedGoogle Scholar
  107. 107.
    El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC et al (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49:116–123PubMedCrossRefGoogle Scholar
  108. 108.
    Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La VC et al (2002) Does coffee protect against hepatocellular carcinoma? Br J Cancer 87:956–959PubMedCrossRefGoogle Scholar
  109. 109.
    Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML et al (2005) Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 42:528–534PubMedCrossRefGoogle Scholar
  110. 110.
    Tanaka K, Hara M, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y et al (2007) Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 98:214–218PubMedCrossRefGoogle Scholar
  111. 111.
    Talamini R, Polesel J, Montella M, Dal ML, Crispo A, Tommasi LG et al (2006) Food groups and risk of hepatocellular carcinoma: a multicenter case-control study in Italy. Int J Cancer 119:2916–2921PubMedCrossRefGoogle Scholar
  112. 112.
    Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ (1995) Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 55:1301–1305PubMedGoogle Scholar
  113. 113.
    Demir G, Belentepe S, Ozguroglu M, Celik AF, Sayhan N, Tekin S et al (2002) Simultaneous presentation of hepatocellular carcinoma in identical twin brothers. Med Oncol 19:113–116PubMedCrossRefGoogle Scholar
  114. 114.
    Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM (2003) Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 9:2428–2432PubMedGoogle Scholar
  115. 115.
    Zhang JY, Wang X, Han SG, Zhuang H (1998) A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg 59:947–951PubMedGoogle Scholar
  116. 116.
    Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L et al (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30:379–383PubMedCrossRefGoogle Scholar
  117. 117.
    Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ et al (2000) Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 92:1159–1164PubMedCrossRefGoogle Scholar
  118. 118.
    Chen CH, Huang GT, Lee HS, Yang PM, Chen DS, Sheu JC (1998) Clinical impact of screening first-degree relatives of patients with hepatocellular carcinoma. J Clin Gastroenterol 27:236–239PubMedCrossRefGoogle Scholar
  119. 119.
    Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM et al (2002) Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 31:1008–1015PubMedCrossRefGoogle Scholar
  120. 120.
    Donato F, Gelatti U, Chiesa R, Albertini A, Bucella E, Boffetta P et al (1999) A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 10:417–421CrossRefGoogle Scholar
  121. 121.
    Piperno A (1998) Classification and diagnosis of iron overload. Haematologica 83:447–455PubMedGoogle Scholar
  122. 122.
    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399–408PubMedCrossRefGoogle Scholar
  123. 123.
    Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R et al (1996) Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 22:187–194PubMedCrossRefGoogle Scholar
  124. 124.
    Bullen JJ, Rogers HJ, Griffiths E (1978) Role of iron in bacterial infection. Curr Top Microbiol Immunol 80:1–35PubMedGoogle Scholar
  125. 125.
    Bullen JJ, Ward CG, Rogers HJ (1991) The critical role of iron in some clinical infections. Eur J Clin Microbiol Infect Dis 10:613–617PubMedCrossRefGoogle Scholar
  126. 126.
    Miller M, Crippin JS, Klintmalm G (1996) End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Am J Gastroenterol 91:1427–1429PubMedGoogle Scholar
  127. 127.
    Hayashi H, Takikawa T, Nishimura N, Yano M (1995) Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22:268–271PubMedCrossRefGoogle Scholar
  128. 128.
    Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A et al (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147PubMedCrossRefGoogle Scholar
  129. 129.
    Bonkovsky HL, Banner BF, Rothman AL (1997) Iron and chronic viral hepatitis. Hepatology 25:759–768PubMedCrossRefGoogle Scholar
  130. 130.
    Sifers RN, Finegold MJ, Woo SL (1992) Molecular biology and genetics of alpha 1-antitrypsin deficiency. Semin Liver Dis 12:301–310PubMedCrossRefGoogle Scholar
  131. 131.
    Fabbretti G, Sergi C, Consales G, Faa G, Brisigotti M, Romeo G et al (1992) Genetic variants of alpha-1-antitrypsin (AAT). Liver 12:296–301PubMedGoogle Scholar
  132. 132.
    Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314:736–739PubMedCrossRefGoogle Scholar
  133. 133.
    Blenkinsopp WK, Haffenden GP (1977) Alpha-1-antitrypsin bodies in the liver. J Clin Pathol 30:132–137PubMedCrossRefGoogle Scholar
  134. 134.
    Carlson J, Eriksson S (1985) Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol 20:835–842PubMedCrossRefGoogle Scholar
  135. 135.
    Zhou H, Fischer HP (1998) Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 22:742–748PubMedCrossRefGoogle Scholar
  136. 136.
    Teckman JH, Qu D, Perlmutter DH (1996) Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology 24:1504–1516PubMedGoogle Scholar
  137. 137.
    Banner BF, Karamitsios N, Smith L, Bonkovsky HL (1998) Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol 93:1541–1545PubMedCrossRefGoogle Scholar
  138. 138.
    Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152(Suppl 1):S63–S70PubMedCrossRefGoogle Scholar
  139. 139.
    Siersema PD, ten Kate FJ, Mulder PG, Wilson JH (1992) Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 12:56–61PubMedGoogle Scholar
  140. 140.
    Cheng WS, Govindarajan S, Redeker AG (1992) Hepatocellular carcinoma in a case of Wilson’s disease. Liver 12:42–45PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Manal M. Hassan
    • 1
  • Ahmed O. Kaseb
    • 1
  1. 1.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations